Staff Software Engineer, Infrastructure
FreenomeSalary not specified
- Full Time
- Junior (1 to 2 years)
About Freenome
Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in blood samples. This method allows for non-invasive early detection of cancer, which is crucial for effective treatment. Freenome differentiates itself from competitors by its unique combination of data analysis techniques and its commitment to clinical trials and research collaborations. The company's goal is to enhance cancer diagnostics and make early detection accessible to healthcare providers and patients, ultimately aiming to save lives through timely intervention.
San Francisco, CaliforniaHeadquarters
2014Year Founded
$1,032.6MTotal Funding
LATE_VCCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Competitive market-based salaries
Annual bonus opportunities
Relocation packages
Medical, dental, & vision coverage
401k
Wellness programs
Equity
PTO
Risks
Employee layoffs may affect morale and innovation efforts.
Integration of Oncimmune Ltd. could divert focus from core projects.
Competitive landscape in cancer detection may impact Freenome's market share.
Differentiation
Freenome uses a unique multiomics approach for early cancer detection.
The company focuses on non-invasive blood tests for cancer screening.
Freenome's platform designs personalized health conditions based on cell-free genome analysis.
Upsides
Recent $254 million funding boosts clinical programs and platform expansion.
Partnership with Walgreens enhances clinical trial diversity and patient recruitment.
PROACT LUNG study positions Freenome as a leader in lung cancer diagnostics.
Funding
Total raised$1.03 B
Latest valuation$1.50 B
StageLATE_VC
LATE VC
1/31/2024- DCVC
- Pura Vida Investments
- Roche Venture Fund
- Bain Capital Life Sciences
- Perceptive Advisors
- Andreessen Horowitz
- Artis Ventures
- Intermountain Ventures
- Eventide Asset Management
- T. Rowe Price
- Cormorant Capital
- Quest Diagnostics
- RA Capital Management
- Polaris Partners
- BrightEdge
- Squarepoint Capital
- ArrowMark Partners
- ARK Invest
- Section 32
$254
$1.50 BSERIES D
11/30/2021- DCVC
- Pura Vida Investments
- Sands Capital Management
- Roche Venture Fund
- Logos Capital
- Janus Henderson Investors
- Bain Capital Life Sciences
- Perceptive Advisors
- Andreessen Horowitz
- Artis Ventures
- HBM Healthcare Investments
- Intermountain Ventures
- Eventide Asset Management
- Kaiser Permanente
- Byers Capital
- Cormorant Capital
- RA Capital Management
- Farallon Capital Management
- Fidelity Investments
- Polaris Partners
- Soleus Capital
- BrightEdge
- ArrowMark Partners
- Rock Springs Capital
- Ridgeback Capital
- Catalio Capital Management
- Section 32
- Novartis
- Suvretta Capital Management
$300
$1.50 BSERIES C
7/31/2020- DCVC
- EcoR1 Capital
- Sands Capital Management
- Roche Venture Fund
- Cormorant Asset Management
- Janus Henderson Investors
- Bain Capital Life Sciences
- Perceptive Advisors
- Andreessen Horowitz
- The Colon Cancer Alliance
- T. Rowe Price
- RA Capital Management
- Farallon Capital Management
- Fidelity Investments
- Polaris Partners
- Soleus Capital
- BrightEdge
- Rock Springs Capital
- Catalio Capital Management
- Section 32
- Novartis
- Kaiser Permanente Ventures
$270
$1.35 B$6
$28.00 M